New biological treatments show promise for psoriasis
Washington - Biological treatments for psoriasis have largely unraveled the once-secret mechanisms behind this disease. "The biologics including Amevive [alefacept], Raptiva [efalizumab], Embrel [etanercept], and Remicade [infliximab] are scientifically revolutionary and exciting," said John Y. M. Koo, M.D., who spoke about these treatments at the American Academy of Dermatology meeting. Board-certified in dermatology and psychiatry, he is professor and vice chairman of the University of California at San Francisco's department of dermatology.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.